$SRRK

Scholar Rock (NasdaqGS: SRRK) reported Q2 2026 results with a net loss of $109.9 million and basic loss per share of $0.84. The company updated its apitegromab SMA BLA strategy, advancing the application using two independent fill-finish facilities to support FDA review ahead of a 30 Sep 2026 PDUFA date and potential European regulator steps.

Scholar Rock Holding (NASDAQ: SRRK) reported a Q2 2026 loss of $0.84 per share, slightly better than the $0.86 expected, with no revenue as it remains pre-commercial. Net loss was $109.9 million. The loss narrowed from $0.98 in Q2 2025. Shares were largely unchanged; analysts show 14 buys, 1 hold, 0 sells.

Scholar Rock Holding Corp (SRRK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srrk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-fi

Biotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.

Biotech stocks outperformed the broader market this year as investors rotated into growth and as M&A activity picked up, according to a Wedbush interview on BNN Bloomberg. The report cites an $11 billion AbbVie deal for Apogee. Wedbush highlighted Kiniksa (Q revenue $214M; raised guidance), Monte Rosa (Phase 2 updates), and Scholar Rock (FDA PDUFA Sept. 30; revenue estimates $163M in 2027, $450M in 2028).

Scholar Rock (NASDAQ: SRRK) announced that its management will participate in the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET. The company, which specializes in therapies for spinal muscular atrophy and other neuromuscular diseases, will provide a live webcast of the presentation. A replay will also be available on Scholar Rock's investor relations website for approximately 90 days following the event.

Barclays analyst Etzer Darout has raised the price target for Scholar Rock Holding (SRRK) to $55, maintaining an Overweight rating due to the company's progress in developing therapies for rare neuromuscular diseases. Despite this positive outlook, the company has a low GF Score™ of 31/100, indicating financial weaknesses, and has seen significant insider selling worth $5.0 million over the last three months. Investors are advised to consider these mixed signals cautiously.

Holocene Advisors LP has acquired a new stake of 2,461,596 shares in Scholar Rock Holding Corporation (NASDAQ:SRRK) valued at $91.67 million during the third quarter. This acquisition makes Holocene Advisors LP owner of approximately 2.56% of Scholar Rock's stock. Other institutional investors have also increased their holdings in SRRK, while company insiders have recently sold shares.

Redmile Group, LLC significantly increased its stake in Scholar Rock Holding Corporation, buying 1,316,390 shares worth an estimated $49.37 million. This investment boosts Redmile Group's position to 16.94% of its reportable assets under management. Scholar Rock's shares have climbed 25.7% over the past year, indicating investor confidence ahead of a planned Biologics License Application resubmission for apitegromab.

Scholar Rock Holding Corp's stock reached a 52-week high of $48.46, reflecting a 17.15% increase over the past year and a 28.19% return over six months. Despite analysts not anticipating profitability this year, the company's focus on innovative treatments and a strong financial position, with a $4.94 billion market capitalization and a current ratio of 6.3, contribute to growing investor confidence. Analyst ratings are largely positive, emphasizing the potential of its drug candidate apitegromab, even with a recent FDA warning letter to a manufacturing partner.